NEOCEF 100MG/5ML
Manufacturer
Laboratórios Atral, S.A., Portugal
Applicant company
TV TPI CO. LTD.
Active ingredient
Cefixime (dưới dạng Cefixime trihydrate 112mg/5ml)
Content
100mg/5ml
Shelf life
24 months
Dosage Form
Powder for oral suspension
Package
Box of 1 bottle x 60ml, with a 5ml measuring spoon. Box of 1 bottle x 120ml, with a 5ml measuring spoon
Visa Number
560110331025
Issuing Date
17/07/2025
Therapeutic area
Antibiotics
Indication
Treatment of infections caused by susceptible bacteria as follows:
- Acute exacerbation of chronic bronchitis.
- Community-acquired pneumonia.
- Lower urinary tract infections.
- Pyelonephritis.
Treatment of otitis media, sinusitis, and pharyngitis.
The use of cefixime should be reserved for cases where the causative pathogen is known or suspected to be resistant to commonly used antibiotics, or when treatment failure could pose a significant risk.
Official guidance on the appropriate use of antibacterial agents should be taken into consideration.
Dosage
Adults and children over 10 years of age (weighing more than 50 kg)
The recommended dose is 200 - 400 mg/day depending on the severity of the infection, administered as a single daily dose or in two divided doses.
Elderly patients
Elderly patients should use the same recommended dose as adults. Renal function should be monitored, and dose adjustment is required for patients with severe renal impairment.
Children under 10 years of age (weighing less than 50 kg) - Oral suspension
The recommended dose for children is 8 mg/kg/day administered as a single daily dose or in two divided doses. The recommended daily dose for children by strength and volume is as follows:
| Weight (kg) / Age | Daily dose (mg) | Daily dose (ml) |
|---|---|---|
| 6 months to 1 year | 75 mg | 3.75 ml |
| Children from 1 - 4 years | 100 mg | 5 ml |
| Children from 5 - 10 years | 200 mg | 10 ml |
Children under 6 months of age
The safety and efficacy of cefixime have not been established in children under 6 months of age.
Renal impairment
Cefixime may be administered in the presence of impaired renal function. Patients with creatinine clearance (CrCl) ≥ 20 ml/min may be given the normal dose. In patients with CrCl < 20 ml/min, it is recommended that a dose of 200 mg once daily should not be exceeded. The dose and regimen for patients maintained on chronic ambulatory peritoneal dialysis or hemodialysis should follow the same recommendation as for patients with CrCl < 20 ml/min.
Contact

